Targeting signal transducer and activator of transcription 3 pathway by cucurbitacin I diminishes self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133 + cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 341, Issue 2, 2012, Pages 410-423

  Tseng, Ling Ming ^a,b   Huang, Pin I ^a,b   Chen, Yu Rung ^a,b   Chen, Yu Chih ^a,b   Chou, Yueh Ching ^a,b   Chen, Yi Wei ^a,b   Chang, Yuh Lih ^a,b   Hsu, Han Shui ^a,b   Lan, Yuan Tzu ^a,b   Chen, Kuan Hsuan ^a,b   Chi, Chin Wen ^a,b   Chiou, Shih Hwa ^a,b   Yang, De Ming ^a,b   Lee, Chen Hsen ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CUCURBITACIN; CUCURBITACIN I; IODINE 125; RADIOACTIVE IODINE; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ABCG2 GENE; ADULT; AGED; ANAPLASTIC CARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENICITY; CELL DIFFERENTIATION; CHEMORADIOTHERAPY; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MALE; MDR1 GENE; MICROARRAY ANALYSIS; MOUSE; MRP GENE; NANOG GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; OCT4A GENE; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN TARGETING; RADIOSENSITIVITY; SOX2 GENE; SURVIVAL TIME; THYROID CANCER; TUMOR GENE; UPREGULATION;

ANIMALS; ANTIGENS, CD; APOPTOSIS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; GLYCOPROTEINS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; PEPTIDES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; THYROID NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TRITERPENES; UP-REGULATION;

EID: 84859994573     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.188730     Document Type: Article

References (40)

1. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, and Sebti SM (2003) Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 63:1270-1279. (Pubitemid 36348705)
2. Bollrath J and Greten FR (2009) IKK/NF-κB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep 10:1314-1319.
3. Bowman T, Garcia R, Turkson J, and Jove R (2000) STATs in oncogenesis. Oncogene 19:2474-2488. (Pubitemid 30339203)
4. Bromberg J (2002) Stat proteins and oncogenesis. J Clin Invest 109:1139-1142.
5. Bromberg JF (2001) Activation of STAT proteins and growth control. Bioessays 23:161-169.
6. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, and Darnell JE Jr (1999) Stat3 as an oncogene. Cell 98:295-303. (Pubitemid 29380565)
7. Carvalho DP and Ferreira AC (2007) The importance of sodium/iodide symporter (NIS) for thyroid cancer management. Arq Bras Endocrinol Metabol 51:672-682.
8. Castro P, Rebocho AP, Soares RJ, Magalhães J, Roque L, Trovisco V, Vieira de Castro I, Cardoso-de-Oliveira M, Fonseca E, Soares P, et al. (2006) PAX8-PPARγ rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 91:213-220.
9. + cells. J Cell Mol Med 15:612-624.
10. Chiou SH, Kao CL, Chen YW, Chien CS, Hung SC, Lo JF, Chen YJ, Ku HH, Hsu MT, and Wong TT (2008) Identification of CD133-positive radioresistant cells in atypical teratoid/rhabdoid tumor. PLoS One 3:e2090.
11. Corbeil D, Röper K, Hellwig A, Tavian M, Miraglia S, Watt SM, Simmons PJ, Peault B, Buck DW, and Huttner WB (2000) The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 275:5512-5520. (Pubitemid 30115186)
12. Cornett WR, Sharma AK, Day TA, Richardson MS, Hoda RS, van Heerden JA, and Fernandes JK (2007) Anaplastic thyroid carcinoma: an overview. Curr Oncol Rep 9:152-158. (Pubitemid 46332389)
13. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, Li Y, Wang JM, Yang-Yen HF, Karras J, et al. (2001) Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 107:351-362.
14. Fenton MS, Marion KM, Salem AK, Hogen R, Naeim F, and Hershman JM (2010) Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer. Thyroid 20:965-974.
15. Francipane MG, Eterno V, Spina V, Bini M, Scerrino G, Buscemi G, Gulotta G, Todaro M, Dieli F, De Maria R, et al. (2009) Suppressor of cytokine signaling 3 sensitizes anaplastic thyroid cancer to standard chemotherapy. Cancer Res 69:6141-6148.
16. + anaplastic thyroid cancer cells initiate tumors in immunodeficient mice and are regulated by thyrotropin. PLoS One 4:e5395.
17. Furuya F, Shimura H, Suzuki H, Taki K, Ohta K, Haraguchi K, Onaya T, Endo T, and Kobayashi T (2004) Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. Endocrinology 145:2865-2875. (Pubitemid 38686236)
18. Hilbe W, Dirnhofer S, Oberwasserlechner F, Schmid T, Gunsilius E, Hilbe G, Wöll E, and Kähler CM (2004) CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J Clin Pathol 57:965-969. (Pubitemid 39208249)
19. Hwang JH, Kim DW, Suh JM, Kim H, Song JH, Hwang ES, Park KC, Chung HK, Kim JM, Lee TH, et al. (2003) Activation of signal transducer and activator of transcription 3 by oncogenic RET/PTC (rearranged in transformation/papillary thyroid carcinoma) tyrosine kinase: roles in specific gene regulation and cellular transformation. Mol Endocrinol 17:1155-1166. (Pubitemid 36683722)
20. Jordan CT, Guzman ML, and Noble M (2006) Cancer stem cells. N Engl J Med 355:1253-1261. (Pubitemid 44427449)
21. Kao CL, Huang PI, Tsai PH, Tsai ML, Lo JF, Lee YY, Chen YJ, Chen YW, and Chiou SH (2009) Resveratrol-induced apoptosis and increased radiosensitivity in CD133-positive cells derived from atypical teratoid/rhabdoid tumor. Int J Radiat Oncol Biol Phys 74:219-228.
22. Kim DW, Chung HK, Park KC, Hwang JH, Jo YS, Chung J, Kalvakolanu DV, Resta N, and Shong M (2007) Tumor suppressor LKB1 inhibits activation of signal transducer and activator of transcription 3 (STAT3) by thyroid oncogenic tyrosine kinase rearranged in transformation (RET)/papillary thyroid carcinoma (PTC). Mol Endocrinol 21:3039-3049. (Pubitemid 350223513)
23. Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC, Park SH, Hwang JH, Rha SY, Kweon GR, et al. (2006) An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 91:4070-4076. (Pubitemid 44536887)
24. Kim TH, Lee SY, Rho JH, Jeong NY, Soung YH, Jo WS, Kang DY, Kim SH, and Yoo YH (2009) Mutant p53 (G199V) gains antiapoptotic function through signal transducer and activator of transcription 3 in anaplastic thyroid cancer cells. Mol Cancer Res 7:1645-1654.
25. Kim YR, Byun HS, Won M, Park KA, Kim JM, Choi BL, Lee H, Hong JH, Park J, Seok JH, et al. (2008) Modulatory role of phospholipase D in the activation of signal transducer and activator of transcription (STAT)-3 by thyroid oncogenic kinase RET/PTC. BMC Cancer 8:144.
26. Lee DH, Iwanski GB, and Thoennissen NH (2010) Cucurbitacin: ancient compound shedding new light on cancer treatment. Scientific World Journal 10:413-418.
27. Marques AR, Espadinha C, Catarino AL, Moniz S, Pereira T, Sobrinho LG, and Leite V (2002) Expression of PAX8-PPARγ1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 87:3947-3952. (Pubitemid 34879553)
28. Niu G, Wright KL, Ma Y, Wright GM, Huang M, Irby R, Briggs J, Karras J, Cress WD, Pardoll D, et al. (2005) Role of Stat3 in regulating p53 expression and function. Mol Cell Biol 25:7432-7440. (Pubitemid 41170107)
29. O'Brien CA, Kreso A, and Jamieson CH (2010) Cancer stem cells and self-renewal. Clin Cancer Res 16:3113-3120.
30. Park JW, Zarnegar R, Kanauchi H, Wong MG, Hyun WC, Ginzinger DG, Lobo M, Cotter P, Duh QY, and Clark OH (2005) Troglitazone, the peroxisome proliferator-activated receptor-γ agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid 15:222-231. (Pubitemid 40418689)
31. Riesco-Eizaguirre G and Santisteban P (2006) A perspective view of sodium iodide symporter research and its clinical implications. Eur J Endocrinol 155:495-512. (Pubitemid 44608424)
32. Singh A and Settleman J (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29:4741-4751.
33. Sipos JA and Mazzaferri EL (2010) Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol) 22:395-404.
34. Spitzweg C (2009) Gene therapy in thyroid cancer. Horm Metab Res 41:500-509.
35. Spitzweg C, Joba W, Morris JC, and Heufelder AE (1999) Regulation of sodium iodide symporter gene expression in FRTL-5 rat thyroid cells. Thyroid 9:821-830. (Pubitemid 29409667)
36. Sugino K, Ito K, Mimura T, Nagahama M, Fukunari N, Kubo A, Iwasaki H, and Ito K (2002) The important role of operations in the management of anaplastic thyroid carcinoma. Surgery 131:245-248. (Pubitemid 34229776)
37. Wilhelm S and Gedrich RW (2010) inventors; Bayer Healthcare LLC, assignees. Treatment of cancers having resistance to chemotherapeutic agents. U.S. patent 20100173954. 1995 Jul 8.
38. Yu H and Jove R (2004) The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 4:97-105. (Pubitemid 38198738)
39. Yu H, Pardoll D, and Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9:798-809.
40. pos cancer stem-like cells in anaplastic thyroid carcinoma cell lines. PLoS One 3:e3544.